Sandoz Pharma Ltd.
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sandoz Pharma Ltd.
Humira Biosimilars Prepare For US Competition In 2023
The advent of biosimilar competition to Humira in the US in 2023 represents the largest loss-of-exclusivity opportunity ever for the off-patent industry. But with a host of biosimilar sponsors awaiting launches throughout the year, it remains to be seen how competition will play out.
Asia Deal Watch: Astellas Seeks Pantherna’s Assistance On mRNA-Based Regenerative Medicine
Plus deals involving OliPass/Vanda, Simcere/Almirall, Sinopharm/Merck & Co., Jiuzhou/Sandoz, Zai Lab/Seagen, Sciwind/SynderK, Hansoh/KiOmed.
China Halts UCB's Keppra Injection Sales
China halts import, sales and use of the widely prescribed epilepsy drug.
China Halts UCB's Keppra Injection Sales
China halts import, sales and use of the widely prescribed epilepsy drug.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice